D-0342-2025 Class II Ongoing
FDA drug recall D-0342-2025 was initiated by Glenmark Pharmaceuticals Inc., USA on Mar 13, 2025 and is designated Class II. Reason for recall: CGMP Deviations The recall status is ongoing.
Recall details
- Product Type
- Drugs
- Report Date
- Apr 16, 2025
- Initiation Date
- Mar 13, 2025
- Voluntary/Mandated
- Voluntary: Firm initiated
Product description
Diltiazem Hydrochloride Extended-Release Capsules 12HR 120mg, 100-count bottle, Rx, Only. Manufactured by: Glenmark Pharmaceuticals Limited, Pithampur, Madhya Pradesh 454775, India, Manufactured for: Glenmark Pharmaceuticals Inc. USA, Mahwah, NJ 07430. NDC# 68462-562-01
Reason for recall
CGMP Deviations
Distribution pattern
U.S. Nationwide
Code information
Lot # 17241067, exp. date May-26 17241628, exp. date Aug-26
Source
- Dataset
- openFDA drug recall enforcement reports
- FDA record
- This recall in openFDA (JSON)
- Enforcement Report
- Search FDA's Enforcement Report for D-0342-2025
- openFDA file date
- Nov 10, 2026
- Loaded by RegDataLab
- Nov 11, 2026